top of page

Our drugs target the peripheral cannabinoid receptors which are expressed in the immune system, vaginal tissue and intestinal mucosa leading to a quiescent state which is unfavorable for HIV transmission and replication. THIS SECTION NEEDS TO BE EXPANDED TO INCLUDE GSM OR GENERICALLY WOMEN'S HEALTH.   If it is agreed to include menopause treatments we will add a tab for pipeline.  (also not sure if image is accurate or needs to be changed - suggestions?)

A New Paradigm in the Treatment and Prevention of Women's health Risks and Conditions

 ACHIEVING QUIESCENCE

Our drugs target the peripheral cannabinoid receptors which are expressed in the immune system, vaginal tissue and intestinal mucosa leading to a quiescent state which is unfavorable for HIV transmission and replication. THIS SECTION NEEDS TO BE EXPANDED TO INCLUDE GSM OR GENERICALLY WOMEN'S HEALTH.   If it is agreed to include menopause treatments we will add a tab for pipeline.  (also not sure if image is accurate or needs to be changed - suggestions?)

A New Paradigm in the Treatment and Prevention of Women's health Risks and Conditions

Test Tubes

 CANNABIS PHARMACEUTICALS

Increasing Demand and R&D

 

The stigma around medical cannabis is lifting and in exchange the market is expected to reach $28 billion in 2024, according to Energias Market Research.  Increased awareness, demand, and R&D initiatives with a pharmaceutical approach to medical research, are engines for this growth. 

Cannabis is a complex plant with over 400 active pharmaceutical ingredients of which more than 60 of them are cannabinoid compounds. The FDA recognizes the potential opportunities that cannabis or cannabis-derived compounds may offer, and recent medical studies have shown that various cannabinoid combinations may be effective in treating a wide range of medical conditions and disorders.

Test Tubes

 CANNABIS PHARMACEUTICALS

Increasing Demand and R&D

 

The stigma around medical cannabis is lifting and in exchange the market is expected to reach $28 billion in 2024, according to Energias Market Research.  Increased awareness, demand, and R&D initiatives with a pharmaceutical approach to medical research, are engines for this growth. 

Cannabis is a complex plant with over 400 active pharmaceutical ingredients of which more than 60 of them are cannabinoid compounds. The FDA recognizes the potential opportunities that cannabis or cannabis-derived compounds may offer, and recent medical studies have shown that various cannabinoid combinations may be effective in treating a wide range of medical conditions and disorders.

bottom of page